Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some vaccines will definitely be in trouble the more interest the press take:
https://www.msn.com/en-gb/health/medical/multiple-concerns-raised-over-oxford-s-coronavirus-vaccine-with-some-wondering-if-high-efficacy-was-a-chance-finding/ar-BB1bnUCE?ocid=msedgntp
Maybe he was born twice: once in Manchester, for the purpose of the EU project, and then again in Manchester, New Hampshire, for the US study? :-)
Wow... so impressive, he's certainly not wasted his time, think you safely say we are in good hands...
1. Take two views before selling
2. Buy more
3. Rinse and repeat.
Here is the link again.
https://hstalks.com/t/4467/update-on-the-sng001-drug-an-inf-therapy-for-covid/?biosci&nocache
Apologies I meant to say lancet 12th not 19th. On the move and texting
The Prof Holgate interview was published on 19th November - a week ago. Therefore we can safely assume it was conducted between the date of the lancet RNS on the 13th Nov and the 19th.
pmjh..... continued thanks for all you do here, battling on despite some pretty dreadful posters on here of late.... enough to make you give up completely!
Assuming this interview was between 12th-19th November, when it was published, there will be a few more enrolled.
I printed out the home trial and pinned it up in my doctors waiting room a few days ago..... I have always found in life that's it's best to just get on and do it yourself......
Info king ‘ which make me think this interview was taken several weeks ago. ‘
He mentions the lancet article from last week 19th nov .
So your dates are incorrect re thinking the interview was several weeks ago
Agree that Prof Holgate is an academic and that academics focus on is the next piece of research and that's very obvious from this cracking interview BUT this drug saves lives, it's quite obvious other priorities have preceeded getting awareness of the home trial out...
Mattw
It’s only natural for the government (regardless of how incompetent they are) to promote a vaccine ahead of therapeutics
Hence the sng share price tanking
As always, prevention is better than the cure
BruceJamieson - there seems to be a lot of things you are not aware of. Perhaps you should listen more to what is going on out there in the world and not just rely on what you think is going on.
The Government supported the Plasma trials. The Government supported the vaccine trials.
What a stupid thing to say.
Matt Han**** has actively supported the recovery trials. He has actively named the vaccine phase 3 trials.
It’s strange that on the NIHR website that it says the home trial is now closed. There is also a link for “ covidtrialathome” which takes you to the trial enrolment page suggesting it is our trial And it looks very much open. I’d have thought the NIHR website would have been more accurate.
I am not aware that any governments support clinical trials. What a strange idea
I think people are getting a bit to hung up on the 30. He says we currently have 30 enrolled on the home trial. To me this suggests patients which are being monitored and not those that have completed the trial. We also don’t know the date of the interview, he does say a few things which make me think this interview was taken several weeks ago. Some very big positives here, just wish it was advertised and shared more widely.
Expanding the Home trials into America makes perfect sense. Especially with the UKGOV has failed so badly to support this Phase2 trial.
Matml- it was a good find, thank you. Lots of very positive information. Let’s get an answer from the company on actual numbers first before soiling our pants. In the meantime, there were tons of other positives to focus on. We don’t need to go on about one point we’re unsure of and add fuel to the fire for the likes of Sheman.
So many different applications. The "30" doesn't bother me much it's phase 111 I'm waiting on.
Bloody hell. Kind of wish I hadn't found that interview!
There was much more positive in that interview than negative yet people have picked up on the 30 number. Richard specifically said the home trial news would be next big piece of info to come so hopefully the 30 patients mentioned were those currently being treated. In any case there should be some clarification for shareholders of this by the company.
Prof Holgate is an academic and there was much mention of trial after trial in this interview. All the academics I have ever dealt with all they ever focus on is the next piece of research. Prof Holgate can clearly see the bigger picture for this drug and it really is an exciting prospect for this drugs future, the idea of prophylaxis and prevention of not just covid but many other viral lung infections.
What frustrates me is that Professor Holgate can give a webinar to an audience who are not even shareholders and he can update them with information that even the LTH don't even know? Why is that? Why are we not getting good communication from Richard?
Tbh Oil I’ve had a break for a couple of weeks from SNG and it feels to me people are more frustrated with the SP than anything else and it’s over spilling. Totally understandable. I just think even if you forget covid this drug will be invaluable once it gains approvals. Market cap is £160 million. Minimum price for this is £600m upon a successful phase III trial. Personally I believe we will need therapeutics for COVID-19 for another winter or two yet and then there is the whole cast of respiratory viruses existing today and future ones that haven’t hit us yet that SNG001 will have application for.
Well i hope your right Miggy, I'm not convinced. It would be helpfull if the company could clarify their position to the shareholders though. Instead we are all trying to figure out what is going on by snippets from webcasts, webcasts from people who have more information than us, it's not right.
The fastest way to approvals is through hospital trials as we are dealing with larger numbers which the regulators will want to see for various data sets. It has meant home trial being on the back burner. I also suspect home trial data is harder to quantify unlike a secure setting like a hospital where access to patients means results and observation is easier. I trust the company knows the fastest route to market and we should have faith in that. You know RM and Prof SH have far more money invested in this than we do.
On all probability it must be 30 on trial currently taking treatment.
From the numbers in my previous post. The worst case scenario would need to assume for 7 months we had zero uptake on the trial. Although possible this has to be very unlikely.
Its hard to tell if he meant 30 enrolled currently taking treatment or he meant 30 currently enrolled in total for the trial.
RM said they had virtually no takeup over summer and since October have been getting 1 or 2 a day on average. When he says October most thought he meant Oct 1st maybe he meant from Oct 31st! Stephens interview was Nov 19th so using 1 or 2 a day on average of 30 gives us around 20 days to fill maybe? So it could take us back to Oct 31st.
The 30 number would also need to assume we had zero takeup since the trial began what 8 months ago. That surely cant be the case?
I honestly don't know the answer :)